More early data displaying promise in CAR-T field

Celyad (Euronext Brussels: CYAD) has announced promising CAR-T cell therapy results in colorectal cancer (mCRC).

The Belgian biotech firm, seen as a leader in the CAR-T field and now partnering with Swiss pharma giant Novartis (NOVN: VX), has presented early clinical results at the three-month follow-up of the first dose-level in the solid tumor arm of a study entitled THINK (THerapeutic Immunotherapy with CAR-T NKR-2).

NKR-2 CAR T-cell therapy was designed to act as a targeted therapy with short term persistence and multiple injections in order to provide a better controlled and more predictable safety profile.